

Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.[®] (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2018, and provide a general business overview on Thursday, August 9, 2018, at 8:30 a.m. ET (5:30 a.m. PT).

Conference Call Details

The live conference call on Thursday, August 9, 2018, at 8:30 a.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 6650817. The webcast can be accessed live on the Investor Relations section of the Company's website at <http://investors.portola.com>. It will be archived for 30 days following the call.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company's two FDA-approved medicines are Bevyxxa[®] (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness, and Andexxa[®] [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.

Investor Contact:

Cara Miller
Portola Pharmaceuticals
ir@portola.com

Media Contact:

Laurie Masonson
Pure Communications
lmasonson@purecommunications.com

Portola Pharmaceuticals, Inc.



<https://investors.portola.com/2018-08-02-Portola-Pharmaceuticals-to-Announce-Second-Quarter-2018-Financial-Results-and-Host-Conference-Call-on-Thursday-August-9-2018>